BioSpace News Archive

Business

Apertura Launches Leveraging Harvard, MIT Gene Therapy Platforms: Updated

With $67 million in Series A financing, newly-launched Apertura plans to develop genetic medicines using technologies that address key limitations of gene delivery and expression.

April 26, 2022
·
4 min read
·
Alex Keown
Policy

Is the US Running Blind Toward COVID-19 Boosters?

How many boosters are enough to protect against COVID-19 infection? This question has been at the forefront of the minds of everyone as news crops up about yearly boosters.

April 26, 2022
·
2 min read
·
Hayley Shasteen
Business

The 9 Things Wildly Successful Biotechs Have in Common

Successful biotech companies have a certain way of thinking that propels everyone working there beyond day-to-day concerns and enables them to do great things. BioSpace highlights nine commonalities.

April 26, 2022
·
5 min read
·
Gail Dutton
Sandoz, Zolgensma, Drive Strong Q1 for Novartis

Novartis’ Sandoz business unit saw a strong financial performance in the first quarter of 2022, with overall sales growth of 8%, mostly outside of the United States.

April 26, 2022
·
3 min read
·
Alex Keown
Drug Development

Protagonist Forges Ahead with UC Drug On Strength of Low Dose Data

Protagonist Therapeutics’ Phase II study of an ulcerative colitis treatment failed to meet its primary endpoint at a higher dosage amount. Even so, the company remains optimistic about the drug’s future.

April 26, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Roche MS Trial Woes Highlight Current Perils of Reliance on Eastern Europe

The war has shattered plans for a variety of clinical trials, but Roche is particularly concerned about fenebrutinib, a drug it is developing for multiple sclerosis (MS).

April 26, 2022
·
4 min read
·
Hannah Chudleigh
Drug Development

Editas, VBL and Pharming Score Regulatory Wins On Development Journey

Editas Medicine snagged Rare Pediatric Disease designation for its experimental beta thalassemia gene therapy, while VBL received Fast Track designation for an ofra-vec combination in ovarian cancer.

April 26, 2022
·
3 min read
·
Alex Keown
Drug Development

Pheast Garners $76M to Launch Therapy Targeting Elusive Cancer Protein

Pheast Therapeutics launched today with $76 million in Series A financing. Pheast is focused on developing cancer checkpoint therapies to fight malignant cells, focusing on ovarian and breast cancers.

April 26, 2022
·
2 min read
·
Hayley Shasteen
Business

Nektar Cuts 70% of Workforce on Heels of BMS-Partnered Collapse

Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70% of its workforce. This comes only weeks after BMS abandoned its clinical collaboration program with Nektar.

April 26, 2022
·
3 min read
·
Mark Terry
Study: Inhibiting ATX Improves Ability to Recover from Stroke

A new approach to improving a patient’s ability to recover from a stroke is discussed in an article published this month in Science Translational Medicine.

April 26, 2022
·
2 min read
·
Jazmine Colatriano